Right to Try, expanded access use, Project Facilitate, and clinical trial reform [0.03%]
《特批用药、扩大用药途径、赞助用藥以及临床试验改革》
N K Reddy,V Subbiah
N K Reddy
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al [0.03%]
关于D.Fabrizio等人发表的“基于159872例癌症患者的现实世界流行率支持TMB-H用于定义帕博利珠单抗治疗的转移性实体瘤”的评论文章
D J McGrail,P G Pilié,N U Rashid et al.
D J McGrail et al.
Deep learning for diagnosis and survival prediction in soft tissue sarcoma [0.03%]
深度学习在软组织肉瘤诊断和生存预测中的应用
S Foersch,M Eckstein,D-C Wagner et al.
S Foersch et al.
Background: Clinical management of soft tissue sarcoma (STS) is particularly challenging. Here, we used digital pathology and deep learning (DL) for diagnosis and prognosis prediction of STS. ...
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer [0.03%]
纳武单抗联合卡铂、紫杉醇和贝伐单抗一线治疗晚期非鳞状细胞非小细胞肺癌
S Sugawara,J-S Lee,J-H Kang et al.
S Sugawara et al.
Background: This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung ...
TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061 [0.03%]
在KEYNOTE-061研究中，PD-L1 TMB界值不能预测胃食管腺癌患者接受Pd-1抑制剂治疗的疗效
M B Foote,S B Maron,A Cercek et al.
M B Foote et al.
Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer [0.03%]
临床选择在转移性去势抵抗性前列腺癌治疗强化中的应用
R Iacovelli,C Ciccarese,G Tortora
R Iacovelli
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial [0.03%]
原发性前列腺肿瘤在转移性雄激素敏感性前列腺癌中的转录分析及其与临床结果的关系：E3805 CHAARTED试验的相关分析
A A Hamid,H-C Huang,V Wang et al.
A A Hamid et al.
Background: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in ...
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [0.03%]
Trodelvy治疗转移性三阴乳腺癌III期ASCENT研究的生物标志物分析
A Bardia,S M Tolaney,K Punie et al.
A Bardia et al.
Background: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked wi...
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights [0.03%]
聚腺苷二磷酸核糖聚合酶抑制剂治疗后的与治疗相关的骨髓瘤：新的分子见解
J E Martin,S Khalife-Hachem,T Grinda et al.
J E Martin et al.
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials [0.03%]
用于癌症患者的PARP抑制剂和新发继发性恶性肿瘤：安慰剂随机对照试验的系统评价与安全性 Meta 分析
P-M Morice,I Ray-Coquard,K N Moore et al.
P-M Morice et al.